IDH1 and central nervous system cancer: Additionally, in a recent study of grade III glioma patients treated with radiotherapy and either temozolomide or nitrosourea, IDH mutation status was found to be a significant prognostic factor for PFS (hazard ratio HR] = 0.59) and OS (HR = 0.42) 24.